Karyopharm Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript
All right. Good afternoon, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference. I'm Michael Ulz, one of the biotech analysts here, and it's my pleasure to introduce the team from Karyopharm, including Richard Paulson, CEO; as well as Reshma Rangwala, CMO.
And just a reminder, the format for today is a fireside chat. And before we get started, I just need to read a quick disclosure statement. So for important disclosures, please see the Morgan Stanley Research disclosure website at www.morganstanley.com/researchdisclosures.
If you have any questions, please reach out to your Morgan Stanley sales representative. And with that, maybe I'll turn it over to you, Richard, just for some introductory comments for people that may not be familiar with Karyopharm, and then we can get into the Q&A.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |